Oulin Bio Shareholders' Meeting: Major Staphylococcus aureus Vaccine Results Imminent, Second Indication Underway; Still Needs to Overcome Dependence on Single Product

① The change in gross margin of the main product in 2025 is mainly due to the upgrade of packaging materials to more convenient pre-filled syringes, resulting in increased costs and a slight decline in gross margin; ② Oulin Bio's Staphylococcus aureus vaccine has completed the enrollment of all subjects in the national Phase III clinical trial, and data unblinding is expected to be completed in the first half of this year.

cls.cnApr 22 09:36

CSC Financial: The phased production of biologics continues to advance, benefiting capacity optimization and efficiency improvement.

The Notice specifies regulatory requirements for the segmented production of biological products, establishing a comprehensive operational guideline. This notice comprises six provisions, offering provincial drug regulatory authorities a complete set of operational guidelines for segmented production licensing and oversight.

Zhitong FinanceApr 10 14:35

CSC Financial: The batch release of vaccine industry products declined year-on-year in 2025, with multiple key products approved for market launch.

In 2025, the total number of batch releases in the vaccine industry reached 3,793 batches, representing an 11.3% year-on-year decrease. This decline was primarily driven by significant reductions in the number of batch releases for products such as polio vaccines, meningitis vaccines, encephalitis vaccines, and measles-mumps-rubella vaccines.

Zhitong FinanceFeb 12 10:58

Sinovac Pharmaceuticals Aims for Dual A+H Listing, Valued at 6.2 Billion USD, Yet Innovation Potential May Be Limited

In the past two years, the trend of "A+H" listings has surged again. To date, more than 100 A-share companies are at various stages of going public in Hong Kong. (Refer to the list of A+H dual-listed companies at the end of this article.) Among these, there are no shortage of biopharmaceutical firms; Hengrui Pharma has already successfully listed on the Hong Kong stock exchange, while Baili Tianhe remains stuck at the final stage of its listing process. Additionally, Sinovac Biotech, Maiwei Bio, Changchun High-Tech, Beta Pharma, Yuekang Pharma, Zelgen Biopharma, SinoPharm Nova, Yifang Bio, Oulin Bio, and Bai Bioscience have all submitted their applications to the Hong Kong Stock Exchange. According to Gelonghui, Sinovac Biotech Co., Ltd. (referred to as: Sinovac Pharma) has submitted its application to the Hong Kong Stock Exchange.

Gelonghui FinanceFeb 11 17:58

IPO Prospect | Leading Tetanus Vaccine Maker Goes Public in Hong Kong: Can Oulin Bio (688319.SH) Tell a Compelling IPO Story?

As the undisputed leader in China’s tetanus vaccine sector, Oulin Bio has consistently captured approximately 70% of the market share with its flagship product, the adsorbed tetanus vaccine, establishing a stable revenue base.

Zhitong FinanceDec 7, 2025 17:50